title: Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori.
abstract: Although the majority of primary gastric lymphomas are of high-grade non-Hodgkin's type, a significant number are low-grade B cell lymphomas. The recognition that the majority of the latter have characteristic clinicopathological features that are different from those of their nodal counterparts has led to the suggestion that these lymphomas arise specifically from within organized extranodal lymphoid tissue; this tissue resembles that seen constitutively in the intestine (mostly located in the terminal ileum as Peyer's patches) and is termed mucosa-associated lymphoid tissue (MALT). The paradox of this proposal is that there is no MALT in the gastric mucosa in normal individuals from which a primary lymphoma can arise. However, it has been shown that organized lymphoid tissue with all the features of MALT can be acquired in the gastric mucosa, and this is seen most frequently, but not exclusively, in association with infection by Helicobacter pylori (H. pylori). Subsequent studies have confirmed a close association between H. pylori infection and gastric MALT lymphoma with the infection preceding the development of the lymphoma. In vitro studies have demonstrated that there is an immunologically based drive to tumor cell proliferation in low-grade gastric MALT lymphomas associated with the presence of H. pylori. Clinical studies have shown that, at least in early lesions, eradication of the organism can result in tumor regression in 60 to 92% of cases.
authors.affiliation: Department of Histopathology, Royal Marsden Hospital, London, United Kingdom.
authors.forename: A C
authors.initials: AC
authors.lastname: Wotherspoon
mesh_terms: D002455:Cell Division / Q000276:immunology; D005753:Gastric Mucosa / Q000473:pathology; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D016480:Helicobacter pylori / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007082:Ileum / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008221:Lymphoid Tissue / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000150:complications / Q000473:pathology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications* / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000473:pathology; D010581:Peyer's Patches / Q000473:pathology; D012074:Remission Induction; D013272:Stomach Diseases / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D013274:Stomach Neoplasms / Q000150:complications* / Q000276:immunology / Q000473:pathology / Q000517:prevention & control